{"id":53470,"title":"AstraZeneca Poised for Potential Valuation Uplift as Heart Drug Trial Results Loom","publisher":"Stockmark.IT","author":"Stockmark.IT Website","published":"2026-05-31T09:32:38+00:00","modified":"2026-05-31T09:32:38+00:00","canonical_url":"https://stockmark.it/astrazeneca-poised-for-potential-valuation-uplift-as-heart-drug-trial-results-loom/","markdown_url":"https://stockmark.it/astrazeneca-poised-for-potential-valuation-uplift-as-heart-drug-trial-results-loom.md","json_url":"https://stockmark.it/astrazeneca-poised-for-potential-valuation-uplift-as-heart-drug-trial-results-loom.json","category":"Pharmaceutical","categories":["Pharmaceutical"],"tags":["AstraZeneca","ATTR cardiomyopathy","Citi analysis","pharmaceutical trials","TTR silencer","Wainua"],"featured_image":"https://stockmark.it/wp-content/uploads/2026/05/magnific_create-impactful-images-t_rlBQRDpxtc.avif","format":"news","language":"en-GB","content":"Citi has identified an attractive risk-reward scenario for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) in advance of headline data from a critical trial of its cardiac treatment Wainua, with results anticipated during the third quarter of 2026.\n\nWainua functions as a TTR-silencer, inhibiting the production of transthyretin (TTR), a protein that can misfold and deposit within cardiac tissue and nerves. This accumulation leads to a degenerative condition termed ATTR-cardiomyopathy (ATTR-CM).\n\nThe CARDIO-TTRansform trial represents a phase three investigation assessing Wainua’s therapeutic efficacy in ATTR-CM patients. This indication encompasses a substantially larger and more commercially attractive patient population compared to the peripheral nerve disorder for which the drug has already secured regulatory approval.\n\nCiti estimates a comparatively high likelihood that the trial will achieve its primary endpoint. Success would elevate the bank’s peak sales forecast for Wainua in ATTR-CM to $6 billion, rising to $7 billion when combined with revenues from the existing neurological indication. This projection significantly exceeds the risk-adjusted consensus estimate of approximately $3 billion and would translate to a 2% enhancement in Citi’s discounted cash flow valuation.\n\nShould a secondary endpoint demonstrate clinical benefit in patients already receiving stabiliser medications, Citi anticipates peak ATTR-CM sales could reach $8 billion, with total Wainua revenues approaching $9 billion. Such an outcome would confer a 4% discounted cash flow uplift to the firm’s valuation model.\n\nConversely, trial failure would result in a 3% discounted cash flow reduction. However, Citi emphasises that even under this adverse scenario, its valuation would remain more than 20% above the prevailing share price. This suggests that investors should view any share price weakness stemming from disappointing trial results as a potential accumulation opportunity."}